GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (FRA:DV3R) » Definitions » Cyclically Adjusted Revenue per Share

Delcath Systems (FRA:DV3R) Cyclically Adjusted Revenue per Share : €407.35 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Delcath Systems Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Delcath Systems's adjusted revenue per share for the three months ended in Mar. 2024 was €0.116. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €407.35 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Delcath Systems's average Cyclically Adjusted Revenue Growth Rate was -11.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -14.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Delcath Systems was -14.10% per year. The lowest was -28.00% per year. And the median was -19.75% per year.

As of today (2024-05-18), Delcath Systems's current stock price is €6.30. Delcath Systems's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €407.35. Delcath Systems's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Delcath Systems was 5348.74. The lowest was 0.01. And the median was 0.02.


Delcath Systems Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Delcath Systems's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Cyclically Adjusted Revenue per Share Chart

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.93 569.32 498.93 425.28 396.97

Delcath Systems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 436.00 428.95 439.29 396.97 407.35

Competitive Comparison of Delcath Systems's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Delcath Systems's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Cyclically Adjusted PS Ratio falls into.



Delcath Systems Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Delcath Systems's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.116/131.7762*131.7762
=0.116

Current CPI (Mar. 2024) = 131.7762.

Delcath Systems Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 287.000 104.136 363.178
201712 297.500 104.011 376.916
201803 569.000 105.290 712.138
201806 734.000 106.317 909.769
201809 13.843 106.507 17.127
201812 59.933 105.998 74.508
201903 2.276 107.251 2.796
201906 3.578 108.070 4.363
201909 3.382 108.329 4.114
201912 6.940 108.420 8.435
202003 3.644 108.902 4.409
202006 0.148 108.767 0.179
202009 0.092 109.815 0.110
202012 0.070 109.897 0.084
202103 0.050 111.754 0.059
202106 0.067 114.631 0.077
202109 0.059 115.734 0.067
202112 0.239 117.630 0.268
202203 0.042 121.301 0.046
202206 0.092 125.017 0.097
202209 0.099 125.227 0.104
202212 0.060 125.222 0.063
202303 0.048 127.348 0.050
202306 0.037 128.729 0.038
202309 0.023 129.860 0.023
202312 0.022 129.419 0.022
202403 0.116 131.776 0.116

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Delcath Systems  (FRA:DV3R) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Delcath Systems's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.30/407.35
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Delcath Systems was 5348.74. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Delcath Systems Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (FRA:DV3R) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems (FRA:DV3R) Headlines

No Headlines